Our Publications

Scientific publications

2018 - 2019

Lachaine J, Beauchemin C, Bibeau J, Patenaude J, Pratap C, Proulx J and Bougie. Canadian Economic Impact of Improved Workplace Productivity in Patients with Major Depressive Disorder Treated with Vortioxetine. CNS Spectrum. 2019; 1-8. doi: 10.1017/S1092852919000853
Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Tran T, Mates M, Lemieux J, Chabot P, Prady C, Couture F, Lachaine J. Real-world patient- and caregiver-reported outcomes in advanced breast cancer. Curr Oncol. 2018 Aug;25(4):e282-e290.
Lachaine J, Miron A, Beauchemin C, The iGenoMed Consortium. Economic evaluations of treatments for inflammatory bowel diseases: a literature review. Canadian Journal of Gastroenterology and Hepatology. 2018; 2018:7439730. doi:10.1155/2018/7439730

2016 - 2017

Ágh T, Pawaskar M, Nagy B, Lachaine J, Vokó Z. The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA. Clin Drug Investig. 2016 Apr;36(4):305-12.
Lachaine J, Sikirica V, Mathurin K. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD. BMC Psychiatry. 2016 Jan 16;16:11.

2014 - 2015

Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015 Nov;25(11):3282-94.
Beauchemin C, Johnston JB, Lapierre M, Aissa F, Lachaine J. Relation between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis. Current Oncology, 2015;DOI:10.3747/co.22.2119.
Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E. Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia. Canadian Journal of Psychiatry, 2015;60(3 Suppl 2):S40-S47.
Lachaine J, Mathurin K, Barakat S, Couban S. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. European Journal of Haematology, 2015;DOI:10.1111/ejh.12475.
Bartlett G, Rahimzadeh V, Longo C, Orlando LA, Dawes M, Lachaine J, Bochud M, Paccaud F, Bergman H, Crimi L, Issa AM. The future of genomic testing in primary care: the changing face of personalized medicine. Personalized Medicine, 2014;11(5):477-486.
Lachaine J, De G, Sikirica V, van Stralen J, Hodgkins P, Yang H, Heroux J, Ben Amor L. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in Quebec. Canadian Journal of Psychiatry, 2014 Nov;59(11):597-608.
Lachaine J, Mathurin K, Barakat S, Schuh A. Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukemia in Canada. Hematological Oncology, 2014 Nov;DOI:10.1002/hon.2176.
Ben Amor L, Sikirica V, Cloutier M, Lachaine J, Guerin A, Carter V, Hodgkins P, van Stralen J. Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in Quebec. Journal of the Canadian Academy of Child and Adolescent Psychiatry (JCACAP), 2014 Sep;23(3):157-166.
Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. Journal of Medical Economics, 2014 Apr;17(4):296-304.
Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M. Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada. BMC Psychiatry, 2014 Jan 22;14(1):16.

2012 - 2013

Levesque A, Lachaine J, Bissonnette R. Risk of myocardial infarction in Canadian patients with psoriasis: a retrospective cohort study. Journal of Cutaneous Medicine and Surgery, 2013 Nov-Dec;17(6):398-403.
Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. The European Journal of Health Economics, 2013 Aug 9.
Lachaine J, Beauchemin C, Crochard A, Bineau S. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l’assurance maladie du Québec database. Canadian Journal of Psychiatry, 2013 Apr;58(4):195-200.
Lachaine J, Yen L, Beauchemin C, Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterology, 2013 Jan 30;13:23.
Lachaine J, Beauchemin C, Sasane R, Hodgkins PS. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. PostGraduate Medicine, 2012 May;124(3):139-48.
Lachaine J, Beauchemin C. Economic evaluation of dexmedetomidine relative to midazolam for sedation in the intensive care unit. Canadian Journal of Hospital Pharmacy, 2012 Mar;65(2):103-10.

2010 - 2011

Lachaine J, Beauchemin C, Legault M, Bineau S. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Canadian Journal of Psychiatry, 2011 Oct;56(10):596-604.
Lachaine J, Beauchemin C, Ramos E. Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clinical Pharmacology, 2011 May;11(4).
Rinfret S, Kennedy WA, Lachaine J, Lemay A, Rodés-Cabau J, Cohen DJ, Costerousse O, Bertrand OF. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen. JACC Cardiovascular Interventions, 2010 Oct;3(10):1011-9.
Lachaine J, Beauchemin C, Landry PA. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clinical Journal of Pain, 2010 May;26(4):284-90.
Bussières JF, Simoncelli M, Bourdon O, Lachaine J. Doit-on s’inspirer de la tarification à l’activité pour le financement des médicaments onéreux en établissements de santé? Canadian Journal of Hospital Pharmacy, 2010 May-Jun;63(3):236-43.

2008 - 2009

Djafari F, Lesk M, Harasymowycz P, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. Journal of Glaucoma, 2009 Mar;18(3):238-42.
Lachaine J, Hodge WG, Steffensen I, Murray C, Barnes D, Foerster V, Ducruet T, Mensinkai T. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Canadian Journal of Ophathalmology, 2008 Feb;43(1):33-41.
Lachaine J, Petrella R, Merikle E, Ali F. Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data. Canadian Journal of Cardiology, 2008 Apr;24(4):269-73.
Hodge WG, Lachaine J, Steffensen I, Murray C, Barnes D, Foerster V, Ducruet T, Morrison A. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. British Journal of Ophthalmology, 2008 Jan;92(1):7-12.

2006 - 2007

Lachaine J, Merikle E, Tarride JE, Montpetit M, Rinfret S. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets. Clinical Therapeutics, 2007 Mar;29(3):519-28.
Lachaine J, Gordon A, Choinière M, Collet JP, Dion D, Tarride JE. Painful neuropathic disorders: an analysis of the Régie de l’assurance maladie du Québec database. Pain Research & Management, 2007 Spring;12(1):31-7.
Lachaine J. Therapeutic options for the prevention and treatment of postoperative nausea and vomiting: a pharmacoeconomic review. Pharmacoeconomics, 2006;24(10):955-70.
Lachaine J, Rinfret S, Merikle EP, Tarride JE. Persistence and adherence to cholesterol lowering agents: evidence from the Régie de l’assurance maladie du Québec data. American Heart Journal, 2006 Jul;152(1):164-9.

2004 - 2005

Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Supportive Cancer Therapy, 2005 Apr 1;2(3):181-7.

2003 - ...

Lachaine J. Chemotherapy-induced emesis: treatment options. Hospital Pharmacy Europe, Summer 2003:2-3.
Lesk M, Lachaine J. Medical therapy of glaucoma: focus on newer agents. Ophthalmic Practice, 2003;21(2):1-7.
Lachaine J, Valiquette L, Crott R. Economic evaluation of NMP22 in the management of bladder cancer. Canadian Journal of Urology, 2000 Apr;7(2):974-80.

Abstracts

2018 - 2019

Lachaine J.; Beauchemin C.; Bibeau J.; Patenaude J.; Chokka P.; Proulx J.; Bougie J.K. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine. Value in Health. Conference: ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems. Spain. 21 (Supplement 3) (pp S282), 2018.
Lambert-Obry V.; Lafrance J.; Savoie M.; Lachaine J. Type 2 diabetes mellitus: lack of good practices for real-world evidence studies. Value in Health. Conference: ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems. Spain. 21 (Supplement 3) (pp S389), 2018.

2016 - 2017

Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Banerjee R, Mates M, Lemieux J, Chabot P, Prady C, Couture F, Lachaine J A Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer for Patients and Caregivers. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual European Congress, 29 October – 2 November, 2016, Vienna, Austria
Gouault-Laliberté A, Bergeron C, Chalifour J-F, Lafond C, Lachaine J Resources Utilization for the Investigation of Pulmonary Nodules in Quebec. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual European Congress, 29 October – 2 November, 2016, Vienna, Austria
Lambert-.‐Obry V, Gouault‐Lalibert A,Castonguay A, Aubin MJ, Vadboncoeur J, Laliberté M-C, Lachaine J Health Care Resource Utilization and Costs Associated With the Management of Non-Infectious Intermediate, Posterior and Panuveitis in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual European Congress, 29 October – 2 November, 2016, Vienna, Austria
Lachaine J, Larbi M, Melnyk P, Rouleau A, Baribeau V, Stip E Impact of initiation of long-acting injectable antipsychotics on resource utilization in patients with schizophrenia. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual European Congress, 29 October – 2 November, 2016, Vienna, Austria
Lachaine J, Gouault Laliberté A, Miron A, Xenopoulos A Time trade off study for parenteral support in short bowel syndrome in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2016, Washington
Lachaine J, Miron A, Shear N, Alhusayen R The prevalence and incidence of hidradenitis suppurativa in Canada: results from a population-based survey. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2016, Washington
Lachaine J, Miron A, Shear N, Alhusayen R, Resource utilization and quality of llife of patients with hidradenitis suppurativa in Canada: results from a population-based survey, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2016, Washington
Lachaine J, Kouroukis CT Economic evaluation of bendamustine plus rituximab in the first-line treatment of patients with chronic lymphocytic leukemia. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2016, Washington
Lachaine J, Kouroukis CT Budget impact analysis for the first-line and second-line treatment of patients with chronic lymphocytic leukemia, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2016, Washington
Lachaine J, Bitton A, Miron A, Nait Ladjemil D, The iGenoMed Consortium Literature review of the economic impact of treatments for inflammatory bowel diseases, Canadian Digestive Diseases Week (CDDW), February 26-29, 2016, Montreal

2014 - 2015

Lachaine J, Bibeau J, Castonguay A, Piché-Richard V, Barakat S Systematic review on the correlation between lung function or eosinophil levels and quality of life in asthma. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan
Lachaine J, Bibeau J, Castonguay A, Piché-Richard V, Barakat S Systematic review on the correlation between lung function or eosinophil levels and health care resource utilization in asthma. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan
Lachaine J, Bibeau J, Castonguay A, Barakat S. Cost and resource utilization of uncontrolled and persistent asthma in Canada: a systematic literature review. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan
Lachaine J, Lambert-Obry V, Lemay M Literature review of economic evaluations of screening tests for breast cancer. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan
Beauchemin C, Lapierre ME, Letarte N, Yelle L, Lachaine J How to conduct economic evaluations of new treatments for advanced cancer when overall survival data are not available? Results from a systematic literature review. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan
Lachaine J, Gaudet D, Miron A, Tremblay K Hospitalizations in hyperchylomicronemia patients in Quebec, Canada; results from a real-world observational study. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan
Lachaine J, Bibeau J, Mathurin K, Miron A, Beauchemin C, Benmouhoub I, Bouchama N, Cadieux-Chalifour S, Castonguay A, Charron JN, Enckle G, Hasani I, Lambert-Obry V, Lapierre ME, Piché-Richard V Systematic review of economic evaluations in personalized medicine, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan
Lachaine J, Miron A, Nait Ladjemil D Economic evaluations of treatments for inflammatory bowel diseases, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan
Lachaine J, Cyr MC, Mtibaa M, Raymond V, Duong Patient’s adherence to oral anticoagulants in atrial fibrillation. A Canadian Association for Population Therapeutics (CAPT), November 2-3, 2015, Toronto
Cyr MC, Bissonnette R, Lachaine J Effects of methotrexate on the risk of myocardial infarction among Canadian patients with psoriasis and psoriatic arthritis. International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 22-26, 2015, Boston
Lachaine J, Lachance S, Lambert-Obry V, Bibeau J Systematic review of economic evaluations in allogeneic hematopoietic stem cell transplantation. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 16-20, 2015, Philadelphia
Lachaine J, Lambert-Obry V, Gaumond S, Desjardins O Impact of biologics use on depression and anxiety frequency and health care resource utilization in psoriasis: an analysis using the Quebec provincial drug reimbursement program database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam
Gouault-Laliberté A, Bergeron C, Lachaine J Resources utilization for the investigation of pulmonary nodules in a university hospital center in Quebec, Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam
Mathurin K, Beauchemin C, Lachaine J Validation of a global economic model to evaluate the cost-effectiveness of targeted treatments using companion diagnostics in advanced/metastatic cancer treatment using KRAS testing for cetuximab therapy in metastatic colorectal cancer. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam
Mathurin K, Beauchemin C, Lachaine J Development of a global economic model to evaluate the cost-effectiveness of targeted treatments using companion diagnostics in advanced/metastatic cancer treatment. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam
Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E Treatment patterns of long-acting injectable antipsychotics in the province of Quebec International College of Neuropsycopharmacology (CINP), Jun 24-26, 2014, Vancouver
Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E Healthcare costs before and after initiation of long-acting injectable antipsychotics in the province of Quebec. International College of Neuropsycopharmacology (CINP), Jun 24-26, 2014, Vancouver
Lachaine J, Lapierre ME, Beauchemin C, Angyalosi G, Balp MM, Calado F, Debonnett L, Desforges J, Sagkriotis A. Real world evidence on inhaled tobramycin use in CF patients: analysis of the RAMQ data (Canada). European Cystic Fibrosis Conference (ECFC), Jun 11-14, 2014, Gothenburg
Esfahani K, Agulnik JS, Batist G, Brandao G, Tremblay L, Blais N, Kempen LV, Lachaine J, Rousseau C, Cohen V Biopsy-driven study to identify mechanisms of resistance to crizotinib and to evaluate real-world pharmacoeconomics in advanced ALK-positive NSCLC patients American Society of Clinical Oncology (ASCO), May 30-Jun 3, 2014, Chicago
Lachaine J, Miron A, Beauchemin C Economic evaluations of treatments for inflammatory bowel diseases International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Mathurin M, Beauchemin C A proposed global economic model to value companion diagnostics in advanced/metastatic cancer treatment. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Savoie M, Bibeau J Real-world clinical evidence development: an analysis of relevant international models for the potential implementation of such a program in Quebec. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Lambert-Obry V Cost-effectiveness of stiripentol in the treatment of severe myoclonic epilepsy in infancy in Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Lapierre ME, Lakhdari K Chronic obstructive pulmonary disease (COPD) drug utilization: an analysis with the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C Costs of adverse events associated with treatment of hepatitis C virus infection: an analysis using the Quebec provincial drug reimbursement program database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E Resource use and associated costs of depot antipsychotics: an analysis with the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E Depot antipsychotics treatment patterns: an analysis with the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Mathurin K, Barakat S Cost-effectiveness of arsenic trioxide compared with all-trans retinoic acid + idarubicin in the treatment of newly diagnosed acute promyelocytic lymphoma in Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Mathurin K, Barakat S Cost-effectiveness of arsenic trioxide in the treatment of relapsed/refractory acute promyelocytic lymphoma in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Sikirica V, Mathurin K Cost-effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Sikirica V, Mathurin K Cost-effectiveness of guanfacine extended-release as an adjunctive therapy to long-acting stimulants versus long-acting stimulants monotherapy for the treatment of attention-deficit/hyperactivity disorder in Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal
Lachaine J, Ben Amor L, van Stralen J, Sikirica V, Hodgkins P, De G, Yang H, Heroux J Healthcare resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in Quebec, Canada Canadian Agency for Drugs and Technologies in Health (CADTH), Jun 6-9, 2014, Gatineau
Lachaine J, Baril JP, Lambert-Obry V, Beauchemin C Comparison of compliance rates and health care resource utilization between antiretroviral treatment (ART) regimens: an analysis using the Quebec provincial drug reimbursement program database Canadian Conference on HIV/AIDS Research (CAHR), May 1-4, 2014, St-John
Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C Hepatitis C virus infection treatment patterns and associated costs: an analysis of the Quebec provincial reimbursement program database Canadian Digestive Diseases Week/Canadian Association for the Study of the Liver (CDDW/CASL), Feb 8-11, 2014, Toronto

2012 - 2013

Lachaine J, Mathurin K, Barakat S Cost-effectiveness of arsenic trioxide compared with all-trans retinoic acid + idarubicin in the treatment of newly diagnosed acute promyelocytic lymphoma in Canada American Society of Hematology (ASH), Dec 8-10, 2013, New Orleans
Lachaine J, Mathurin K, Barakat S Cost-effectiveness of arsenic trioxide in the treatment of relapsed/refractory acute promyelocytic lymphoma in Canada American Society of Hematology (ASH), Dec 8-10, 2013, New Orleans
Sikirica V, van Stralen J, Cloutier M, Ben Amor L, Hodgkins P, Carter V, Guerin A, Lachaine J Treatment patterns in ADHD children/adolescents using atypical antipsychotics in Quebec Canadian Academy of Child and Adolescent Psychiatry (CACAP), Nov 17-19, 2013, Vancouver
Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C Hepatitis C virus infection treatment completion: an analysis of the Quebec provincial reimbursement program database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin
Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C Cost associated with adverse events and health care resources utilization in hepatitis C virus infection in Quebec, Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin
Lachaine J, Baril JP, Lambert-Obry V, Beauchemin C Health care resource utilization and adherence to antiretroviral treatment (ART) by HIV patients: an analysis with the Quebec (Canada) public drug plan database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin
Lachaine J, Sikirica V, De G, van Stralen J, Ben Amor L, Hodgkins P, Yang H, Heroux J Healthcare resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in Quebec, Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin
Lachaine J, Lapierre ME, Beauchemin C, Balp MM, Calado F, Debonnett L, Desforges J, Sagkriotis A Tobramycin powder for inhalation for the treatment of cystic fibrosis: analysis of the RAMQ data International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin
Lachaine J, Lambert-Obry V, Dionne PA Potential predictors of Alzheimer’s disease: an analysis with the Quebec provincial drug reimbursement program database. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin
Lachaine J, Lambert-Obry V, Dionne PA Health care resources utilization in Alzheimer’s disease: an analysis with the Quebec provincial drug reimbursement program database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin
Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C Health care resources utilization in hepatitis C virus infection and cost associated with adverse events: an analysis of the Quebec provincial drug reimbursement program database American Association for the Study of Liver Diseases (AASLD), Nov 1-5, 2013, Washington DC
Lachaine J, Beauchemin C Trends in health care resources utilization, cost and medication selection in the treatment of diabetes International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Latin America Congress, Sep 12-14, 2013, Buenos Aires
Lachaine J, Baril JP, Beauchemin C, Lambert-Obry V Compliance to antiretroviral agents (ART) and health care resource utilization by HIV patients: an analysis with the Quebec (Canada) public drug plan database Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sep 10-13, 2013, Denver
Lachaine J, Sikirica V, Cloutier M, Ben Amor L, Hodgkins P, van Stralen J, Carter V, Guerin A Period prevalence of therapy combination and switching among children and adolescents with attention deficit/hyperactivity disorder (ADHD) treated with stimulants in Canada International Conference on Pharmacoepidemiology (ISPE), Aug 25-28, 2013, Montreal
Levesque A, Bissonnette R, Prefontaine S, Lapierre ME, Lachaine J Relative risk of myocardial infarction for Canadian patients with psoriasis treated systemically as compared to patients treated with phototherapy International Conference on Pharmacoepidemiology (ISPE), Aug 25-28, 2013, Montreal
Levesque A, Bissonnette R, Prefontaine S, Lachaine J Relative risk of myocardial infarction for Canadian patients with psoriasis treated systemically as compared to patients treated with phototherapy Canadian Dermatologic Association (CDA), Jun 27-30, 2013, Quebec
Ben Amor L, Sikirica V, De G, Lachaine J, van Stralen J, Heroux J, Yang H, Hodgkins P Therapy combination: a prevalent pattern among children and adolescents with attention deficit/hyperactivity disorder treated with stimulants in the canadian province of Quebec 4th World Congress on ADHD (WCADHD), Jun 6-9, 2013, Milan
Mathurin K, Beauchemin C, Lachaine J Economic evaluations conducted for assessment of companion tests in cancer therapy: a literature review International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Mathurin K, Beauchemin C, Lachaine J The cost-effectiveness of companion tests in cancer therapy: a literature review International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Lachaine J, Beauchemin C, Mathurin K, Aissa F Cost-effectiveness of bendamustine in the treatment of rituximab-refractory indolent Non-Hodgkin’s lymphoma in Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Lachaine J, Beauchemin K, Mathurin K, Aissa F Cost-effectiveness of bendamustine in the treatment of relapsed indolent Non-Hodgkin’s and mantle cell lymphomas in Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Lachaine J, Beauchemin C, Lapierre ME, Snow LA Treatment patterns in pediatric antibiotic formulations: an analysis of the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Lachaine J, Beauchemin C, Lapierre ME, Snow LA Utilization trends of various formulations of testosterone: an analysis of the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Lachaine J, Beauchemin C, Lambert-Obry V, Chiva-Razavi S Economic burden associated with ulcerative colitis in Canada: an analysis using the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Lachaine J, Beauchemin C, Desjardins O Use of anti-TNFα agents in the treatment of psoriasis: an analysis of the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Lachaine J, Beauchemin C, Desjardins O Use of biologic agents in the treatment of rheumatoid arthritis: an analysis of the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Lachaine J, Beauchemin C, Chiva-Razavi S Treatment patterns of adalimumab and infliximab in the treatment of Crohn’s disease over a three-year period: a Canadian assessment International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans
Lachaine J, Feagan BG, Martel MJ, Beauchemin C, McHugh K The impact of TNF inhibitors for Crohn’s disease on health care resource utilization: an analysis using the RAMQ database Canadian Digestive Disease Week (CDDW), Mar 1-4, 2013, Victoria
Lachaine J, Moreau A, Beauchemin C, Mathurin K Economic impact of scoliosis in Canada: a RAMQ database analysis International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin
Lachaine J, Lacroix A, Beauchemin C, Hurry M Characteristics of patients and treatments in Cushing disease: an analysis based on the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin
Lachaine J, Serri O, Beauchemin C, Hurry M Characteristics of patients and treatments in acromegaly: an analysis based on the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin
Beauchemin C, Johnston JB, Lapierre M, Aissa F, Lachaine J Relation between progression-free survival and overall survival in chronic lymphocytic leukemia International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin
Lachaine J, Beauchemin C, Crochard A, Bineau S Impact of initiation of treatment with memantine or cholinesterase inhibitors (ChEI) on the use of antipsychotics: analysis of RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin
Lachaine J, Lacroix A, Beauchemin C, Hurry M Characteristics of patients and treatments in Cushing disease: an analysis based on the RAMQ database Canadian Society of Endocrinology and Metabolism (CSEM), Oct 10-13, 2012, Vancouver
Beauchemin C, Johnston JB, Lapierre M, Aissa F, Lachaine J Relation between progression-free survival and overall survival in chronic lymphocytic leukemia European Society for Medical Oncology (ESMO), Sep 28-Oct 2, 2012, Vienna
Lachaine J, Yen L, Beauchemin C, Hodgkins P Factors associated with treatment adherence and persistence in Canadian patients with ulcerative colitis: analysis of the prescription claims from the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia-Pacific Congress, Sep 2-4, 2012, Taipai
Abdalla N, Barbeau M, Lachaine J Budget impact analysis: do Canadian guidelines meet the needs of public drug plan managers? International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington
Lachaine J, Feagan BG, Martel MJ, Beauchemin C, McHugh K The impact of TNF inhibitors for Crohn’s disease on health care resource utilization: an analysis using the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington
Lachaine J, Beauchemin C, Flavin J Risk of complications in type II diabetic patients with renal impairment: an analysis of the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington
Lachaine J, Beauchemin C, Flavin J Health care resources utilization and cost for hypoglycemia and metabolic acidosis in type II diabetes: an analysis of the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington
Lachaine J, Beauchemin C, Mathurin K, Blouin J Productivity losses associated with vision impairment in Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington
Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M, Corson H Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington
Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M, Corson H Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington
Lachaine J Advanced pharmacoeconomics: the QALY - pros and cons Canadian Association for Population Therapeutics (CAPT), May 6-8, 2012, Montreal
Lachaine J, Beauchemin C, Barbeau M Cost-effectiveness of asenapine in the treatment of schizophrenia and bipolar disorder in Canada College International de Neuropharmacologie (CINP), Jun 3-7, 2012, Stockholm

2010 - 2011

Lachaine J, Beauchemin C, Barbeau M Tobramycin inhaled solution utilization in cystic fibrosis patients in a RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 5-8, 2011, Madrid
Lachaine J, Beauchemin C, Yen L, Hodgkins P Economic impact of medication adherence and persistence in the treatment of ulcerative colitis in canada: analyses with the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 5-8, 2011, Madrid
Lachaine J, Beauchemin C, Martel MJ Comorbidities associated with biologics treated diseases International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 5-8, 2011, Madrid
Lachaine J, Beauchemin C, Crochard A, Bineau S Impact of initiation of treatment with memantine or cholinesterase inhibitors (ChEI) on the use of psychotropic drugs: analysis of RAMQ database Clinical Trial in Alzheimer’s Disease (CTAD), Nov 3-5, 2011, San Diego
Touchon J, Lachaine J, Beauchemin C, Crochard A, Rive B, Bineau S Memantine delays the admission of Alzheimer’s disease patients to nursing home: cost-effectiveness analysis in France Clinical Trial in Alzheimer’s Disease (CTAD), Nov 3-5, 2011, San Diego
Lachaine J, Yen L, Beauchemin C, Hodgkins P Determinants of adherence and persistence in the treatment of ulcerative colitis in Canada: analyses with the RAMQ database United European Gastroenterology Week (UEGW), Oct 22-26, 2011, Stockholm
Lachaine J, Beauchemin C Impact of ChEI treatment initiation on psychotropic use. Analyses with the RAMQ database European Federation of Neurological Societies (EFNS), Sep 10-13, 2011, Budapest
Lachaine J, Beauchemin C, Amer R Economic evaluation of dexmedetomidine for sedation in the intensive care Canadian Society for Hospital Pharmacists (CSHP), Aug 6-10, 2011, Vancouver
Lachaine J, Beauchemin C, Martel MJ, Goyette A Health care resources utilization in the management of juvenile idiopathic arthritis. Analyses with the RAMQ Database European Congress of Rheumatology (EULAR), May 25-26, 2011, Londres
Lachaine J, Beauchemin C Economic evaluation of dexmedetomidine for sedation in the intensive care International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2011, Baltimore
Lachaine J, Beauchemin C, Martel MJ, Goyette A Dose variation with adalimumab and infliximab in the treatment of Crohn disease: a Canadian assessment International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2011, Baltimore
Lachaine J, Beauchemin C, Martel MJ, Goyette A Health care resources utilization in the management of juvenile idiopathic arthritis. Analyses with the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2011, Baltimore
Lachaine J, Beauchemin C, Martel MJ, Goyette A Dose variation with adalimumab and infliximab in the treatment of Crohn disease: a Canadian assessment Canadian Digestive Disease Week (CDDW), Feb 26-Mar 1, 2011, Vancouver
Lachaine J, Beauchemin C, Yen L, Hodgkins P Medication adherence and persistence in the treatment of ulcerative colitis. Analysis with RAMQ data Canadian Digestive Disease Week (CDDW), Feb 26-Mar 1, 2011, Vancouver
Lachaine J, Beauchemin C, Martel MJ, Goyette A Dose variation with adalimumab and infliximab in the treatment of Crohn disease: a Canadian assessment European Crohn & Colitis Organization (ECCO), Feb 24-26, 2011, Dublin
Touchon J, Lachaine J, Beauchemin C, Crochard A, Bineau S Memantine delays the admission of Alzheimer’s disease patients to nursing home: cost-effectiveness analysis in the French setting International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 6-9, 2010, Prague
Lachaine J, Beauchemin C, Legault M, Bineau S Impact of memantine treatment initiation on psychotropics use: analyses with the RAMQ database. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 6-9, 2010, Prague
Lachaine J, Beauchemin C, Yen L, Hodgkins P Medication adherence and persistence in the treatment of ulcerative colitis. Analysis with RAMQ data. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 6-9, 2010, Prague
Martel MJ, Ackad N, Lachaine J Incidence and prevalence of endometriosis in Quebec International Society for Pharmacoepidemiology (ISPE), Aug 19-22, 2010, Brighton
Brault C, Rinfret S, Lachaine J Cost-utility analysis of anti-smoking treatments International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 15-19, 2010, Atlanta
Lachaine J, Beauchemin C, Legault M Economic evaluation of escitalopram to treat major depressive disorder International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 15-19, 2010, Atlanta
Lachaine J, Beauchemin C, Legault M, Le Lay A Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer’s disease International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 15-19, 2010, Atlanta
Lachaine J, Beauchemin C, Hodgkins P, Sasane R Treatment patterns in attention-deficit/hyperactivity disorder. Analyses with the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 15-19, 2010, Atlanta
Lachaine J, Beauchemin C, Sasane R, Hodgkins P Adherence and persistence to treatment in patients with attention-deficit/hyperactivity disorder. Analyses with RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 15-19, 2010, Atlanta

2008 - 2009

Lachaine J, Beauchemin C, Ramos E Use of spironolactone to treat congestive heart failure post-myocardial infarction. Analyses with the RAMQ database Canadian Cardiovascular Congress (CCC), Oct 24-28, 2009, Edmonton
Lachaine J, Beauchemin C, Ramos E Use of spironolactone to treat congestive heart failure post-myocardial infarction. Analyses with the RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Congress, Oct 24-27, 2009, Paris
Lachaine J, Beauchemin C Cost-utility analysis of topical diclofenac for the treatment of osteoarthritis of the knee International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Congress, Oct 24-27, 2009, Paris
Lachaine J, Beauchemin C, Ramos E Use of spironolactone to treat congestive heart failure post-myocardial infarction. Analyses with the RAMQ database International Society for Pharmacoepidemiology (ISPE), Aug 16-19, 2009, Providence
Lachaine J, Beauchemin C Analyse coût-utilité du traitement de l’ostéoarthrite du genou par le diclofénac topique Réseau québécois de recherche sur l’usage des médicaments (RQRUM), Jun 2-3, 2009, Montreal
Lachaine J, Beauchemin C, Ramos E Utilisation de la spironolactone dans le traitement de l’insuffisance cardiaque Réseau québécois de recherche sur l’usage des médicaments (RQRUM), Jun 2-3, 2009, Montreal
Lachaine J, Beauchemin C, Landry PA Caractéristiques cliniques et économiques des patients atteints de fibromyalgie Réseau québécois de recherche sur l’usage des médicaments (RQRUM), Jun 2-3, 2009, Montreal
Lachaine J, Beauchemin C, Landry PA Clinical and economic characteristics of patients with fibromyalgia International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 16-20, 2009, Orlando
Lachaine J Cost-utility analysis of topical diclofenac for the treatment of osteoarthritis of the knee Canadian Agency for Drugs and Technologies in Health (CADTH), Apr 5-7, 2009, Ottawa
Lachaine J, Martel MJ, Poulin YP, Langley R Health care resources utilisation by patients with psoriasis American Academy of Dermatology (AAD), Mar 6-10, 2009, San Francisco
Rinfret S, Kennedy W, Lachaine J, Lemay A, Rodés-Cabau J, Olivier F, Bertrand O The Economic impact of same-day discharge after transradial percutaneous coronary intervention and a single bolus of abciximab; an analysis from the EASY trial American Heart Association, Nov 9-11, 2008, New Orleans
Lachaine J, Martel MJ, Poulin YP, Langley R Health care resources utilisation by patients with psoriasis International Society for Pharmacoepidemiology (ISPE), Aug 16-21, 2008, Copenhagen
Lachaine J, Martel MJ, Poulin YP, Langley R Health care resources utilisation by patients with psoriasis Canadian Association for Population Therapeutics (CAPT), Jul 27-Aug 1, 2008, Quebec

2006 - 2007

Lachaine J, Lescrauwaet B, Sauriol L Treatment patterns in type-2 diabetes management Canadian Diabetes Association (CDA), Oct 18-21, 2006, Toronto
Lachaine J, Lescrauwaet B, Sauriol L Health care resources consumption in type-2 diabetes management Canadian Diabetes Association (CDA), Oct 18-21, 2006, Toronto
Lachaine J, Lescrauwaet B, Sauriol L Treatment patterns in type-2 diabetes management Canadian Association for Population Therapeutics (CAPT), May 10-13, 2006, Toronto
Lachaine J, Lescrauwaet B, Sauriol L Health care resources consumption in type-2 diabetes management Canadian Association for Population Therapeutics (CAPT), May 10-13, 2006, Toronto

2004 - 2005

Dobson R, Henry C, Taylor J, Zello G, Lachaine J The health care team: what role do community pharmacists see for themselves? Canadian Pharmacists Association (CPHA), May 29-31, 2005, Quebec
Lachaine J, Tarride JE Painful neuropathic disorders, an analysis of the RAMQ database Canadian Pain Society (CPS), May 11-14, 2005, Halifax
Lachaine J, Tarride JE Resource utilization in diabetic painful neuropathy patients. An analysis of the RAMQ database Canadian Pain Society (CPS), May 11-14, 2005, Halifax
Lachaine J, Tarride JE Painful neuropathic disorders: an analysis of the Régie de l’assurance maladie du Québec (RAMQ) database Canadian Association for Population Therapeutics (CAPT), Apr 17-19, 2005, Vancouver
Lachaine J, Zlateva G, Charbonneau C Treatment patterns and health care resources utilisation by patients with asthma and COPD Canadian Association for Population Therapeutics (CAPT), Apr 17-19, 2005, Vancouver
Lachaine J, Merickle E, Montpetit M A model of assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian Working Group Guidelines Canadian Association for Population Therapeutics (CAPT), Apr 17-19, 2005, Vancouver
Lachaine J, Tarride JE Resource utilization in diabetic painful neuropathy patients Canadian Association for Population Therapeutics (CAPT), Jun, 2004, Winnipeg
Lachaine J, Ali F, Merikle E Persistence and adherence to antihypertensive agents Canadian Association for Population Therapeutics (CAPT), Jun, 2004, Winnipeg
Lachaine J, Yelle L, Kaiser L, Dufour A, Hopkins S, Deuson R Quality of life and economic impacts of chemotherapy induced nausea and vomiting in the context of current practice in Canada MASCC/ISOO, Jun, 2004, Miami
Lachaine J, Ali F, Merikle E Persistence and adherence to antihypertensive agents American Society of Hypertension (ASH), Jun, 2004, New-York

2003 - ...

Lachaine J, Tarride JE Persistence and adherence to cholesterol lowering agents: evidences from RAMQ data Canadian Association for Population Therapeutics (CAPT), Mar 30-Apr 1, 2003, Quebec
Lachaine J, Yelle L, Kaizer L, Dufour A, Desjardins B, Desjardins B, Deuson R Burden of chemotherapy-induced nausea and vomiting in the context of current Canadian practice European Organization for Research and Treatment of Cancer (EORTC), 2003, Bruxelles
Lachaine J, Yelle L, Kfaizer L, Dufour A, Desjardins B, Desjardins B, Deuson R Incidence and burden of chemotherapy-induced nausea and vomiting in the context of current practice in Ontario and Quebec (Canada) American Society of Clinical Oncology (ASCO), 2003